TruScreen Passes CFDA Technical Assessment for its Second Generation Device in China

Published: 24 November 2017

Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) is pleased to advise that the CFDA has posted on its website that TruScreen has passed Chinese Food and Drug Administration (CFDA) technical assessment and its file has proceeded to the final stage of the approval process. The final culmination of this process would be the formal issuing of the approval certificate.

 

PDF – Announcement Re CFDA Technical Assessment

 -ENDS-